Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 6/2012

01.12.2012 | Review

Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors

verfasst von: Wei-hui Liu, Nan You, Ning Zhang, Hong-tao Yan, Tao Wang, Zhu Huang, Hong-bao Liu, Li-jun Tang

Erschienen in: Cellular Oncology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

In this review, several interlinking issues related to cancer stem cells (CSCs) in malignant solid tumors are sequentially discussed.

Methods

A literature search was performed using PubMed, Web of Science and the Cochrane library, combining the words CSCs, solid tumor, isolation, identification, origination, therapy, target and epithelial–mesenchymal transition.

Results

Because a primary problem is the isolation of CSCs, we first analyzed the advantages and disadvantages of recently used methods, which were mostly based on the physical or immunochemical characteristics of CSCs. Once CSCs are isolated, they should be identified by their stem cell properties. Here, we suggest how to establish a standard identification strategy. We also focused on the origination hypotheses of CSCs. The supporting molecular mechanisms for each theory were thoroughly analyzed and integrated. Especially, epithelial– mesenchymal transition is an increasingly recognized mechanism to generate CSCs that are endowed with a more invasive and metastatic phenotype. Finally, we discuss putative strategies of eliminating CSCs as effective cancer therapies.

Conclusion

After several interlocking issues of CSCs are thoroughly clarified, these CSCs in solid malignant tumors may specifically be targeted, which raises a new hope for eliminating these tumors.
Literatur
1.
H. Clevers, The cancer stem cell: premises, promises and challenges. Nat. Med. 17(3), 313–319 (2011)PubMedCrossRef
2.
T. Ikegami, Transforming growth factor-beta signaling and liver cancer stem cell. Hepatol Res. 39(9), 847–849 (2009)PubMedCrossRef
3.
M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, D.L. Jones et al., Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339–9344 (2006)PubMedCrossRef
4.
M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara et al., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615–5621 (2006)PubMedCrossRef
5.
G. Gu, J. Yuan, M. Wills, S. Kasper, Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67(10), 4807–4815 (2007)PubMedCrossRef
6.
S. Takaishi, T. Okumura, S. Tu, S.S. Wang, W. Shibata, R. Vigneshwaran et al., Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5), 1006–1020 (2009)PubMedCrossRef
7.
M. Todaro, M.G. Francipane, J.P. Medema, G. Stassi, Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 138(6), 2151–2162 (2010)PubMedCrossRef
8.
T. Chiba, A. Kamiya, O. Yokosuka, A. Iwama, Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett. 286(2), 145–153 (2009)PubMedCrossRef
9.
T. Shupe, B.E. Petersen, Evidence regarding a stem cell origin of hepatocellular carcinoma. Stem Cell Rev. 1(3), 261–264 (2005)PubMedCrossRef
10.
M. Baddoo, K. Hill, R. Wilkinson, D. Gaupp, C. Hughes, G.C. Kopen et al., Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89(6), 1235–1249 (2003)PubMedCrossRef
11.
F.I. Ghani, H. Yamazaki, S. Iwata, T. Okamoto, K. Aoe, K. Okabe et al., Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 404(2), 735–742 (2011)PubMedCrossRef
12.
S. Shigdar, J. Lin, Y. Yu, M. Pastuovic, M. Wei, W. Duan, RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102(5), 991–998 (2011)PubMedCrossRef
13.
K. Kohga, T. Tatsumi, T. Takehara, H. Tsunematsu, S. Shimizu, M. Yamamoto et al., Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 52(6), 872–879 (2010)PubMedCrossRef
14.
L. Vermeulen, M. Todaro, F. de Sousa Mello, M.R. Sprick, K. Kemper, M. Perez Alea et al., Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. U. S. A. 105(36), 13427–13432 (2008)PubMedCrossRef
15.
L.S. Hart, N.G. Dolloff, D.T. Dicker, C. Koumenis, J.G. Christensen, A. Grimberg et al., Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10(14), 2331–2338 (2011)PubMedCrossRef
16.
F.J. Abdul Khalek, G.I. Gallicano, L. Mishra, Colon cancer stem cells. Gastrointest Cancer Res 1, S16–S23 (2010)
17.
W. Song, H. Li, K. Tao, R. Li, Z. Song, Q. Zhao et al., Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 62(8), 1212–1218 (2008)PubMedCrossRef
18.
T. Nagata, C. Sakakura, S. Komiyama, A. Miyashita, M. Nishio, Y. Murayama et al., Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 31(2), 495–500 (2011)PubMed
19.
T. Yamashita, J. Ji, A. Budhu, M. Forgues, W. Yang, H.Y. Wang et al., EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136(3), 1012–1024 (2009)PubMedCrossRef
20.
Z.F. Yang, P. Ngai, D.W. Ho, W.C. Yu, M.N. Ng, C.K. Lau et al., Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47(3), 919–928 (2008)PubMedCrossRef
21.
H. Yanai, K. Nakamura, S. Hijioka, A. Kamei, T. Ikari, Y. Ishikawa et al., Dlk-1, a cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency. J. Biochem. 148(1), 85–92 (2010)PubMedCrossRef
22.
B. Christ, P. Stock, M.M. Dollinger, CD13: Waving the flag for a novel cancer stem cell target. Hepatology 53(4), 1388–1390 (2011)PubMedCrossRef
23.
W. Yang, H.X. Yan, L. Chen, Q. Liu, Y.Q. He, L.X. Yu et al., Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 68(11), 4287–4295 (2008)PubMedCrossRef
24.
S. Lingala, Y.Y. Cui, X. Chen, B.H. Ruebner, X.F. Qian, M.A. Zern et al., Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp. Mol. Pathol. 89(1), 27–35 (2010)PubMedCrossRef
25.
Z. Zhu, X. Hao, M. Yan, M. Yao, C. Ge, J. Gu et al., Cancer stem/progenitor cells are highly enriched in CD133 + CD44+ population in hepatocellular carcinoma. Int. J. Cancer 126(9), 2067–2078 (2010)PubMed
26.
X.R. Yang, Y. Xu, B. Yu, J. Zhou, S.J. Qiu, G.M. Shi et al., High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59(7), 953–962 (2010)PubMedCrossRef
27.
T. Fujii, Y. Zen, K. Harada, H. Niwa, S. Masuda, Y. Kaizaki et al., Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma–human and cell culture study. Hum. Pathol. 39(8), 1185–1196 (2008)PubMedCrossRef
28.
M.A. Goodell, K. Brose, G. Paradis, A.S. Conner, R.C. Mulligan, Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183(4), 1797–1806 (1996)PubMedCrossRef
29.
G.J. Spangrude, G.R. Johnson, Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci USA 87(19), 7433–7437 (1990)PubMedCrossRef
30.
A. Asakura, P. Seale, A. Girgis-Gabardo, M.A. Rudnicki, Myogenic specification of side population cells in skeletal muscle. J. Cell Biol. 159(1), 123–134 (2002)PubMedCrossRef
31.
A.J. Alvi, H. Clayton, C. Joshi, T. Enver, A. Ashworth, M.M. Vivanco et al., Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5(1), R1–R8 (2003)PubMedCrossRef
32.
K. Shimano, M. Satake, A. Okaya, J. Kitanaka, N. Kitanaka, M. Takemura et al., Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am. J. Pathol. 163(1), 3–9 (2003)PubMedCrossRef
33.
C.M. Dekaney, J.M. Rodriguez, M.C. Graul, S.J. Henning, Isolation and characterization of a putative intestinal stem cell fraction from mouse jejunum. Gastroenterology 129(5), 1567–1580 (2005)PubMedCrossRef
34.
M. Ono, T. Maruyama, H. Masuda, T. Kajitani, T. Nagashima, T. Arase et al., Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc. Natl. Acad. Sci. U.S.A. 104(47), 18700–18705 (2007)PubMedCrossRef
35.
T. Chiba, K. Kita, Y.W. Zheng, O. Yokosuka, H. Saisho, A. Iwama et al., Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44(1), 240–251 (2006)PubMedCrossRef
36.
G.M. Shi, Y. Xu, J. Fan, J. Zhou, X.R. Yang, S.J. Qiu et al., Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 134(11), 1155–1163 (2008)PubMedCrossRef
37.
Y. Zhang, W.J. Song, F.Q. Zhang, W.H. Liu, K.F. Dou, Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma. Dig. Dis. Sci. 56(8), 2473–2481 (2011)PubMedCrossRef
38.
W.H. Liu, N.S. Qian, R. Li, K.F. Dou, Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. Toxicol. In Vitro 24(2), 538–545 (2010)PubMedCrossRef
39.
W.H. Liu, K.S. Tao, N. You, Z.C. Liu, H.T. Zhang, K.F. Dou, Differences in the Properties and Mirna Expression Profiles between Side Populations from Hepatic Cancer Cells and Normal Liver Cells. PLoS One 6(8), e23311 (2011)PubMedCrossRef
40.
Z. Song, R. Li, N. You, K. Tao, K. Dou, Loss of heterozygosity of the tumor suppressor gene Tg737 in the side population cells of hepatocellular carcinomas is associated with poor prognosis. Mol. Biol. Rep. 37(8), 4091–4101 (2010)PubMedCrossRef
41.
A. Golebiewska, N.H. Brons, R. Bjerkvig, S.P. Niclou, Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8(2), 136–147 (2011)PubMedCrossRef
42.
F. Montanaro, K. Liadaki, J. Schienda, A. Flint, E. Gussoni, L.M. Kunkel, Demystifying SP cell purification: Viability, yield, and phenotype are defined by isolation parameters. Exp. Cell Res. 298(1), 144–154 (2004)PubMedCrossRef
43.
C. Ferlini, G. Scambia, Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat. Protoc. 2(12), 3111–3114 (2007)PubMedCrossRef
44.
A.C. Ribou, J. Vigo, E. Kohen, J.M. Salmon, Microfluorometric study of oxygen dependence of (1″-pyrene butyl)-2-rhodamine ester probe in mitochondria of living cells. J. Photochem. Photobiol. B 70(2), 107–115 (2003)PubMedCrossRef
45.
46.
A.M. Rosca, A. Burlacu, Isolation of a mouse bone marrow population enriched in stem and progenitor cells by centrifugation on a Percoll gradient. Biotechnol. Appl. Biochem. 55(4), 199–208 (2010)PubMedCrossRef
47.
Y. Chang, P.H. Hsieh, C.C. Chao, The efficiency of Percoll and Ficoll density gradient media in the isolation of marrow derived human mesenchymal stem cells with osteogenic potential. Chang Gung Med. J. 32(3), 264–275 (2009)PubMed
48.
W.H. Liu, R. Li, K.F. Dou, Convenient and efficient enrichment of the CD133+ liver cells from rat fetal liver cells as a source of liver stem/progenitor cells. Stem Cell Rev. 7(1), 94–102 (2011)PubMedCrossRef
49.
W.H. Liu, X. Wang, N. You, K.S. Tao, T. Wang, L.J. Tang et al., Efficient Enrichment of Hepatic Cancer Stem-Like Cells from a Primary Rat HCC Model via a Density Gradient Centrifugation-Centered Method. PLoS One 7(4), e35720 (2012)PubMedCrossRef
50.
N.A. Lobo, Y. Shimono, D. Qian, M.F. Clarke, The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675–699 (2007)PubMedCrossRef
51.
M.F. Clarke, M. Fuller, Stem cells and cancer: Two faces of eve. Cell 124(6), 1111–1115 (2006)PubMedCrossRef
52.
X. Lu, Y. Kang, Cell fusion hypothesis of the cancer stem cell. Adv. Exp. Med. Biol. 714, 129–140 (2011)PubMedCrossRef
53.
T. Yamashita, M. Honda, K. Nio, Y. Nakamoto, H. Takamura, T. Tani et al., Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res. 70(11), 4687–4697 (2010)PubMedCrossRef
54.
R. Taghizadeh, M. Noh, Y.H. Huh, E. Ciusani, L. Sigalotti, M. Maio et al., CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One 5(12), e15183 (2010)PubMedCrossRef
55.
A.G. Schepers, H.J. Snippert, D.E. Stange, M. van den Born, J.H. van Es, M. van de Wetering et al., Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095), 730–735 (2012)PubMedCrossRef
56.
A.L. Welm, S. Kim, B.E. Welm, J.M. Bishop, MET and MYC cooperate in mammary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 102(12), 4324–4329 (2005)PubMedCrossRef
57.
B. Mayer, J.P. Johnson, F. Leitl, K.W. Jauch, M.M. Heiss, F.W. Schildberg et al., E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53(7), 1690–1695 (1993)PubMed
58.
S. Sell, Cellular origin of cancer: Dedifferentiation or stem cell maturation arrest? Environ. Health Perspect. 101(Suppl 5), 15–26 (1993)PubMedCrossRef
59.
R. Fossmark, C.M. Zhao, T.C. Martinsen, S. Kawase, D. Chen, H.L. Waldum, Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. APMIS. 113(6), 436–449 (2005)PubMedCrossRef
60.
A.V. Ougolkov, M.E. Fernandez-Zapico, V.N. Bilim, T.C. Smyrk, S.T. Chari, D.D. Billadeau, Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 12(17), 5074–5081 (2006)PubMedCrossRef
61.
Y. Oku, T. Shimoji, K. Takifuji, T. Hotta, S. Yokoyama, K. Matsuda et al., Identification of the molecular mechanisms for dedifferentiation at the invasion front of colorectal cancer by a gene expression analysis. Clin. Cancer Res. 14(22), 7215–7222 (2008)PubMedCrossRef
62.
R.J. Gilbertson, T.A. Graham, Cancer: Resolving the stem-cell debate. Nature 488(7412), 462–463 (2012)PubMedCrossRef
63.
J. Chen, Y. Li, T.S. Yu, R.M. McKay, D.K. Burns, S.G. Kernie et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412), 522–526 (2012)PubMedCrossRef
64.
G. Driessens, B. Beck, A. Caauwe, B.D. Simons, C. Blanpain, Defining the mode of tumour growth by clonal analysis. Nature 488(7412), 527–530 (2012)PubMedCrossRef
65.
A.V. Salnikov, G. Kusumawidjaja, V. Rausch, H. Bruns, W. Gross, A. Khamidjanov et al., Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275(2), 185–193 (2009)PubMedCrossRef
66.
T. Chiba, S. Miyagi, A. Saraya, R. Aoki, A. Seki, Y. Morita et al., The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 68(19), 7742–7749 (2008)PubMedCrossRef
67.
J.P. Li, J.Y. Zheng, J.J. Du, R. Zhang, A.G. Yang, What is the relationship among microRNA-181, epithelial cell-adhesion molecule (EpCAM) and beta-catenin in hepatic cancer stem cells. Hepatology 50(6), 2047–2048 (2009). author reply 448PubMedCrossRef
68.
S. Cairo, Y. Wang, A. de Reynies, K. Duroure, J. Dahan, M.J. Redon et al., Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc. Natl. Acad. Sci. U.S.A. 107(47), 20471–20476 (2010)PubMedCrossRef
69.
R.J. Isfort, D.B. Cody, C.J. Doersen, W.G. Richards, B.K. Yoder, J.E. Wilkinson et al., The tetratricopeptide repeat containing Tg737 gene is a liver neoplasia tumor suppressor gene. Oncogene 15(15), 1797–1803 (1997)PubMedCrossRef
70.
N. You, W. Liu, X. Zhong, R. Ji, M. Zhang, H. You et al., Tg737 inhibition results in malignant transformation in fetal liver stem/progenitor cells by promoting cell-cycle progression and differentiation arrest. Mol. Carcinog. 51(8), 659–673 (2012)PubMedCrossRef
71.
B. Zhang, X. Pan, G.P. Cobb, T.A. Anderson, microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302(1), 1–12 (2007)PubMedCrossRef
72.
C.E. Rogler, MicroRNAs make inroads into liver development. Gastroenterology 136(3), 770–772 (2009)PubMedCrossRef
73.
E.J. Lee, Y. Gusev, J. Jiang, G.J. Nuovo, M.R. Lerner, W.L. Frankel et al., Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046–1054 (2007)PubMedCrossRef
74.
Q.W. Wong, R.W. Lung, P.T. Law, P.B. Lai, K.Y. Chan, K.F. To et al., MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135(1), 257–269 (2008)PubMedCrossRef
75.
R. Liu, Z. Zhou, D. Zhao, C. Chen, The Induction of KLF5 Transcription Factor by Progesterone Contributes to Progesterone-Induced Breast Cancer Cell Proliferation and Dedifferentiation. Mol. Endocrinol. 25(7), 1137–1144 (2011)PubMedCrossRef
76.
S. Chumsri, P. Phatak, M.J. Edelman, N. Khakpour, A.W. Hamburger, A.M. Burger, Cancer stem cells and individualized therapy. Cancer Genomics Proteomics 4(3), 165–174 (2007)PubMed
77.
G. Federici, V. Espina, L. Liotta, K.H. Edmiston, Breast cancer stem cells: A new target for therapy. Oncology (Williston Park) 25(1), 25–28 (2011)
78.
D. Dingli, F. Michor, Successful therapy must eradicate cancer stem cells. Stem Cells 24(12), 2603–2610 (2006)PubMedCrossRef
79.
Y. Liu, W.L. Lu, J. Guo, J. Du, T. Li, J.W. Wu et al., A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 129(1), 18–25 (2008)PubMedCrossRef
80.
J. Gil, A. Stembalska, K.A. Pesz, M.M. Sasiadek, Cancer stem cells: The theory and perspectives in cancer therapy. J. Appl. Genet. 49(2), 193–199 (2008)PubMedCrossRef
81.
L. Milas, W.N. Hittelman, Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin. Radiat. Oncol. 19(2), 96–105 (2009)PubMedCrossRef
82.
Y.L. Hu, Y.H. Fu, Y. Tabata, J.Q. Gao, Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J. Control. Release 147(2), 154–162 (2010)PubMedCrossRef
83.
P. Aimola, V. Desiderio, A. Graziano, P.P. Claudio, Stem cells in cancer therapy: From their role in pathogenesis to their use as therapeutic agents. Drug News Perspect. 23(3), 175–183 (2010)PubMedCrossRef
84.
R. Uchibori, K. Ozawa, [Mesenchymal stem cells (MSCs) as a platform for cancer gene therapy]. Rinsho Ketsueki 51(11), 1641–1646 (2010)PubMed
85.
L.J. Dai, M.R. Moniri, Z.R. Zeng, J.X. Zhou, J. Rayat, G.L. Warnock, Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 305(1), 8–20 (2011)PubMedCrossRef
86.
K. Shah, Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev. 64(8), 739–748 (2012)PubMedCrossRef
87.
I.S. Florian, C. Tomuleasa, O. Soritau, T. Timis, H. Ioani, A. Irimie et al., Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy. J. BUON 16(1), 16–23 (2011)PubMed
88.
H. Beug, Breast cancer stem cells: eradication by differentiation therapy? Cell 138(4), 623–625 (2009)PubMedCrossRef
89.
L. Wijaya, D. Agustina, A.O. Lizandi, M.M. Kartawinata, F. Sandra, Reversing breast cancer stem cell into breast somatic stem cell. Curr. Pharm. Biotechnol. 12(2), 189–195 (2011)PubMedCrossRef
90.
F.A. Kruyt, J.J. Schuringa, Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochem. Pharmacol. 80(4), 423–430 (2010)PubMedCrossRef
91.
S. Sell, Potential gene therapy strategies for cancer stem cells. Curr. Gene Ther. 6(5), 579–591 (2006)PubMedCrossRef
92.
S. Soltanian, M.M. Matin, Cancer stem cells and cancer therapy. Tumour Biol. 32(3), 425–440 (2011)PubMedCrossRef
93.
O.K. Okamoto, J.F. Perez, Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis. Expert Rev. Mol. Diagn. 8(4), 387–393 (2008)PubMedCrossRef
94.
M.R. Alison, S.M. Lim, L.J. Nicholson, Cancer stem cells: problems for therapy? J. Pathol. 223(2), 147–161 (2011)PubMedCrossRef
95.
E. Gorelik, A. Lokshin, V. Levina, Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem. 10(2), 164–171 (2010)PubMedCrossRef
96.
G.J. Leiros, M.E. Balana, Metastatic cancer stem cells: new molecular targets for cancer therapy. Curr. Pharm. Biotechnol. 12(11), 1909–1922 (2011)PubMedCrossRef
97.
M.E. Sehl, J.S. Sinsheimer, H. Zhou, K.L. Lange, Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res. 69(24), 9481–9489 (2009)PubMedCrossRef
Metadaten
Titel
Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors
verfasst von
Wei-hui Liu
Nan You
Ning Zhang
Hong-tao Yan
Tao Wang
Zhu Huang
Hong-bao Liu
Li-jun Tang
Publikationsdatum
01.12.2012
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 6/2012
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0110-8

Weitere Artikel der Ausgabe 6/2012

Cellular Oncology 6/2012 Zur Ausgabe

Original Paper

EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas

Original Paper

Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity

Original Paper

Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion

Original Papers

High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients

Original Paper

HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast

Original Paper

Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Zielgerichtete Therapie Leitthema

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …